文献速递消化系统肿瘤

替莫唑胺治疗改变结直肠癌患者错配修复并提升肿瘤与血液中的突变负荷

Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients.
PubMed 文献 · Cancer Discov · 2022-01-01

ARETHUSA试验纳入MGMT缺陷、错配修复 proficient、RAS突变的转移性结直肠癌患者,接受替莫唑胺引导治疗后,组织活检和循环肿瘤DNA显示出现独特突变特征且肿瘤突变负荷升高;94%(16/17)病例可检出MSH6 p.T1219I变异,部分伴该变异及突变负荷升高的患者经帕博利珠单抗治疗获疾病稳定。

要点

  • 替莫唑胺可在MGMT缺陷、MMR proficient的mCRC中诱导MMR基因改变并升高TMB。
  • 94%(16/17)病例的ctDNA和组织中检出MSH6 p.T1219I变异。
  • 部分伴MSH6变异、TMZ突变特征及TMB升高的患者经帕博利珠单抗治疗达疾病稳定。

核心结论

  • 药理学上可用替莫唑胺使MMR基因失活,并可在mCRC患者组织与血液中进行分子监测。
  • 该策略值得在对标准治疗不再有效的mCRC患者中进一步评估。

研究设计与样本

  • ARETHUSA临床试验:MGMT缺陷、MMR proficient、RAS突变的转移性结直肠癌患者接受替莫唑胺引导治疗。
  • 分析组织活检与循环肿瘤DNA(ctDNA)。

主要发现

  • 替莫唑胺治疗后组织活检和ctDNA出现独特突变特征且TMB升高。
  • MMR基因中出现多个位于替莫唑胺特征偏好核苷酸背景的改变。
  • 94%(16/17)病例的ctDNA和组织中检出p.T1219I MSH6变异。

关键数值与推荐

  • 94%(16/17)病例的ctDNA和组织中检出p.T1219I MSH6变异。
  • 部分肿瘤显示MSH6突变、替莫唑胺突变特征及TMB升高的患者经帕博利珠单抗治疗达疾病稳定。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: The majority of metastatic colorectal cancers (mCRC) are mismatch repair (MMR) proficient and unresponsive to immunotherapy, whereas MMR-deficient (MMRd) tumors often respond to immune-checkpoint blockade. We previously reported that the treatment of colorectal cancer preclinical models with temozolomide (TMZ) leads to MMR deficiency, increased tumor mutational burden (TMB), and sensitization to immunotherapy. To clinically translate these findings, we designed the ARETHUSA clinical trial whereby O6-methylguanine-DNA-methyltransferase (MGMT)-deficient, MMR-proficient, RAS-mutant mCRC patients received priming therapy with TMZ. Analysis of tissue biopsies and circulating tumor DNA (ctDNA) revealed the emergence of a distinct mutational signature and increased TMB after TMZ treatment. Multiple alterations in the nucleotide context favored by the TMZ signature emerged in MMR genes, and the p.T1219I MSH6 variant was detected in ctDNA and tissue of 94% (16/17) of the cases. A subset of patients whose tumors displayed the MSH6 mutation, the TMZ mutational signature, and increased TMB achieved disease stabilization upon pembrolizumab treatment. SIGNIFICANCE: MMR-proficient mCRCs are unresponsive to immunotherapy. We provide the proof of concept that inactivation of MMR genes can be achieved pharmacologically with TMZ and molecularly monitored in the tissue and blood of patients with mCRC. This strategy deserves additional evaluation in mCRC patients whose tumors are no longer responsive to standard-of-care treatments. See related commentary by Willis and Overman, p. 1612. This article is highlighted in the In This Issue feature, p. 1599.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Crisafulli G, Sartore-Bianchi A, Lazzari L, et al. Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients. Cancer Discov. 2022. PMID: 35522273. doi:10.1158/2159-8290.CD-21-1434

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。